+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Coccidioidomycosis Drug"

Coccidioidomycosis - Pipeline Insight, 2024 - Product Thumbnail Image

Coccidioidomycosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Coccidioidomycosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Coccidioidomycosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021 - Product Thumbnail Image

Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 86 Pages
  • Global
From
Coccidioidomycosis - Pipeline Review, H2 2020 - Product Thumbnail Image

Coccidioidomycosis - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 81 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Coccidioidomycosis is an infectious disease caused by the fungus Coccidioides. Treatment of the disease is typically done with antifungal medications, such as fluconazole, itraconazole, and amphotericin B. These medications are used to treat both acute and chronic forms of the disease. The Coccidioidomycosis Drug market is composed of a variety of pharmaceutical companies that produce and distribute these medications. The Coccidioidomycosis Drug market is highly competitive, with many companies offering different formulations of the same medications. Companies in the market include Pfizer, Merck, GlaxoSmithKline, Novartis, and Sanofi. These companies are all major players in the pharmaceutical industry, and they are all involved in the production and distribution of Coccidioidomycosis Drugs. Show Less Read more